praluzatamab ravtansine

CytomX slashes headcount by 40% after breast cancer setback, with later-stage development bearing the brunt
Fierce Biotech
Thu, 07/14/22 - 10:58 am
CytomX Therapeutics
breast cancer
layoffs
praluzatamab ravtansine
CytomX halts lead program and will seek a partner as breast cancer drug disappoints
Endpoints
Thu, 07/7/22 - 10:26 am
clinical trials
CytomX
breast cancer
praluzatamab ravtansine